Medicinal Products

933. Deputy Barry Heneghan asked the Minister for Health if she will engage with the pharmacy sector to ensure that any changes to blister packaging provision do not reduce medication safety for vulnerable patients who depend on organised dosing systems; and if she will make a statement on the matter. [66132/25]

934. Deputy Barry Heneghan asked the Minister for Health if her Department carried out any assessment of the financial or clinical impact of introducing a blister pack charge, particularly for older people and people with disabilities; and if she will make a statement on the matter. [66133/25]

85. Deputy Martin Daly asked the Minister for Health the reason the osteoporosis drug Prolia, denosumab, is not routinely available free of charge to men with confirmed debilitating osteoporosis in Ireland in the same manner as it is available to women in equivalent clinical circumstances; and the steps her Department is taking to ensure equitable access for male patients in the Roscommon–Galway c…

93. Deputy Mairéad Farrell asked the Minister for Health if the decision not to reimburse for belimumab will be reviewed; and if she will make a statement on the matter. [64337/25]

115. Deputy Aindrias Moynihan asked the Minister for Health the up-to-date position on the MCAP review; the way in which and when the membership was constituted; the frequency with which they have met; and when they are due to report; and if she will make a statement on the matter. [64361/25]

118. Deputy Seán Crowe asked the Minister for Health for an update on the approval status of the drug givinostat; if officials from her Department have been in contact with their counterparts in the North of Ireland to examine the possibility of children with Duchenne muscular dystrophy accessing treatment in the North as an interim measure; if not, to outline the barriers to them doing so; and if…

203. Deputy Pádraig O'Sullivan asked the Minister for Health the progress made by her Department regarding the Programme for Government commitment to explore early access schemes for medicines; and if she will make a statement on the matter. [63426/25]

651. Deputy Barry Heneghan asked the Minister for Health if she will examine the current regulatory status of naloxone and consider allowing approved formulations to be made available over-the-counter in order to improve timely access to this emergency medication, in line with international practice; and if she will make a statement on the matter. [64949/25]

652. Deputy Barry Heneghan asked the Minister for Health the current supply pathways through which community and voluntary organisations can access and distribute naloxone; if consideration is being given to expanding these pathways to reduce delays; and if she will make a statement on the matter. [64953/25]

665. Deputy Cormac Devlin asked the Minister for Health to report on the engagement to date between her Department, the HSE and the manufacturer of the Omnipod 5 tubeless hybrid closed-loop insulin delivery system regarding its introduction to the Irish market; if a pricing and reimbursement application has been submitted under the Health (Pricing and Supply of Medical Goods) Act 2013; and if she …

666. Deputy Cormac Devlin asked the Minister for Health if the HSE, NCPE or her Department have undertaken, or plan to undertake, a clinical and cost-effectiveness assessment of the Omnipod 5 tubeless hybrid closed-loop insulin pump system, having regard to its availability and funded use in the UK and other EU member states; if so, to outline the status and expected timelines for a decision; and …

667. Deputy Cormac Devlin asked the Minister for Health her views on the potential role of the Omnipod 5 tubeless hybrid closed-loop insulin system in expanding patient choice for people with type 1 diabetes, including children, people with disabilities, needle or tube aversion, and those with high treatment burden; if she will request the HSE to examine its potential use within the national diabe…

1124. Deputy David Cullinane asked the Minister for Health when a medical product (details supplied) will be available for reimbursement; and if she will make a statement on the matter. [63710/25]

442. Deputy Pádraig Rice asked the Minister for Health further to Parliamentary Question No. 609 of 23 September 2025, to clarify if a group were excluded from the costing for the free hormone replacement therapy (HRT) scheme; if so, to outline how, given the details of an internal communication in relation to the basis for the costing (details supplied); and if she will make a statement on the ma…

457. Deputy Ruth Coppinger asked the Minister for Health further to Parliamentary Questions Nos. 1632 and 1633 of 4 November 2025, whether healthcare providers must indicate eligibility/ineligibility for the free HRT scheme on the prescriptions transmitted to pharmacists; and if she will make a statement on the matter. [62489/25]

965. Deputy Conor Sheehan asked the Minister for Health her plans to roll out a long-acting injection to prevent HIV, as was done by NHS England recently; and if she will make a statement on the matter. [61225/25]

1021. Deputy Michael Healy-Rae asked the Minister for Health the status of an application for medication by a person (details supplied); and if she will make a statement on the matter. [61600/25]

382. Deputy Ken O'Flynn asked the Minister for Health when her Department intends to complete the review of national policy governing the use of medications issued under special licence, as recommended by the Cork city coroner in December 2024; the expected date for finalisation of new protocols on hospital administration and clinician supervision; and if she will make a statement on the matter. …

383. Deputy Ken O'Flynn asked the Minister for Health if her Department has directed the HSE to issue interim guidance or a temporary clinical protocol governing the administration, supervision and recording of special-licence medications in hospitals pending the completion of a full policy review; if she will publish that guidance; and if she will make a statement on the matter. [60517/25]

384. Deputy Ken O'Flynn asked the Minister for Health the number of patients currently in receipt of medications under special licence in Ireland; the number of such patients admitted to hospital in each of the past five years; and the measures being taken to ensure their medication administration is governed by clear and consistent protocols nationwide. [60518/25]

449. Deputy Malcolm Byrne asked the Minister for Health when a person (details supplied) can receive the approved drug repatha (evolocumab) as prescribed; and the current availability of the drug. [60770/25]

459. Deputy Pádraig Rice asked the Minister for Health the number of people on a waiting list for pre-exposure prophylaxis (PrEP) by clinic; and the wait time to be offered a new appointment in each clinic, in tabular form. [60783/25]

482. Deputy Martin Daly asked the Minister for Health the number that have availed of the free HRT scheme since its introduction; and if she will make a statement on the matter. [60878/25]

176. Deputy Colm Burke asked the Minister for Health to outline the number of new medicines which were submitted to the NCPE in each year between 2015 and 2025; and the number of these new medicines that were non-oncology orphan medicinal products, in tabular form; and if she will make a statement on the matter. [60301/25]

177. Deputy Colm Burke asked the Minister for Health to outline the number of non-oncology orphan medicinal products which were referred to the HSE Drugs Group by the NCPE in each year between 2015 and 2025; and to provide a breakdown of the number of successful, negative and pending reimbursement decisions for such products, in tabular form; and if she will make a statement on the matter. [60302/…